These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 31420412)

  • 21. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient outcomes following interval and delayed cytoreductive surgery in advanced ovarian cancer: protocol for a multicenter, international, cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative).
    Gaba F; Ash K; Blyuss O; Bizzarri N; Kamfwa P; Ramirez PT; Kotsopoulos IC; Chandrasekaran D; Gomes N; Butler J; Nobbenhuis M; Ind T; Heath O; Barton D; Jeyarajah A; Brockbank E; Lawrence A; Dilley J; Manchanda R; Phadnis S; Soar GO
    Int J Gynecol Cancer; 2022 Dec; 32(12):1606-1610. PubMed ID: 36379595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE).
    Nitecki R; Rauh-Hain JA; Melamed A; Scambia G; Pareja R; Coleman RL; Ramirez PT; Fagotti A
    Int J Gynecol Cancer; 2020 Sep; 30(9):1450-1454. PubMed ID: 32690591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upfront cytoreductive surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer in Indian patients.
    Ray MD; Deo SSV; Kumar L; Gaur MK
    Future Oncol; 2021 Sep; 17(27):3607-3614. PubMed ID: 34263662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
    Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
    Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
    Wright AA; Bohlke K; Armstrong DK; Bookman MA; Cliby WA; Coleman RL; Dizon DS; Kash JJ; Meyer LA; Moore KN; Olawaiye AB; Oldham J; Salani R; Sparacio D; Tew WP; Vergote I; Edelson MI
    J Clin Oncol; 2016 Oct; 34(28):3460-73. PubMed ID: 27502591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
    Perrone AM; Coada CA; Ravegnini G; De Leo A; Damiano G; De Crescenzo E; Tesei M; Di Costanzo S; Genovesi L; Rubino D; Zamagni C; De Iaco P
    Int J Gynecol Cancer; 2023 Aug; 33(8):1270-1278. PubMed ID: 37429642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Laparoscopic management of advanced epithelial ovarian cancer after neoadjuvant chemotherapy: a phase II prospective multicenter non-randomized trial (the CILOVE study).
    Pomel C; Akladios C; Lambaudie E; Rouzier R; Ferron G; Lecuru F; Classe JM; Fourchotte V; Paillocher N; Wattiez A; Montoriol PF; Thivat E; Beguinot M; Canis M
    Int J Gynecol Cancer; 2021 Dec; 31(12):1572-1578. PubMed ID: 34670829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.
    van de Laar R; Zusterzeel PL; Van Gorp T; Buist MR; van Driel WJ; Gaarenstroom KN; Arts HJ; van Huisseling JC; Hermans RH; Pijnenborg JM; Schutter EM; Pelikan HM; Vollebergh JH; Engelen MJ; Inthout J; Kruitwagen RF; Massuger LF
    BMC Cancer; 2014 Jan; 14():22. PubMed ID: 24422892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MIRRORS: a prospective cohort study assessing the feasibility of robotic interval debulking surgery for advanced-stage ovarian cancer.
    Uwins C; Assalaarachchi H; Bennett K; Read J; Tailor A; Crawshaw J; Chatterjee J; Ellis P; Skene SS; Michael A; Butler-Manuel S
    Int J Gynecol Cancer; 2024 Jun; 34(6):886-897. PubMed ID: 38561194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
    Monk BJ; Coleman RL; Fujiwara K; Wilson MK; Oza AM; Oaknin A; O'Malley DM; Lorusso D; Westin SN; Safra T; Herzog TJ; Marmé F; N Eskander R; Lin KK; Shih D; Goble S; Grechko N; Hume S; Maloney L; McNeish IA; Kristeleit RS
    Int J Gynecol Cancer; 2021 Dec; 31(12):1589-1594. PubMed ID: 34593565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
    Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
    Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
    Wright AA; Bohlke K; Armstrong DK; Bookman MA; Cliby WA; Coleman RL; Dizon DS; Kash JJ; Meyer LA; Moore KN; Olawaiye AB; Oldham J; Salani R; Sparacio D; Tew WP; Vergote I; Edelson MI
    Gynecol Oncol; 2016 Oct; 143(1):3-15. PubMed ID: 27650684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of pattern of recurrence on post-relapse survival according to surgical timing in patients with advanced ovarian cancer.
    Angeles MA; Spagnolo E; Cabarrou B; Pérez-Benavente A; Gil Moreno A; Guyon F; Rychlik A; Migliorelli F; Bataillon G; Navarro AS; Betrian S; Ferron G; Hernández A; Martinez A
    Int J Gynecol Cancer; 2023 Jan; 33(1):50-56. PubMed ID: 36446410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. To compare the optimal cytoreduction rate in advanced epithelial ovarian cancer stage III/IV after 3 versus 6 cycles of neoadjuvant chemotherapy.
    Kumari A; Thakur M; Saha SC; Suri V; Prasad GRV; Patel FD; Radhika S
    J Obstet Gynaecol; 2021 May; 41(4):616-620. PubMed ID: 32811236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial.
    Park SJ; Shim SH; Ji YI; Kwon SH; Lee EJ; Lee M; Chang SJ; Park S; Kim SY; Lee SJ; Kim JW; Roh JW; Lee SH; Song T; Kim HS
    BMC Cancer; 2020 May; 20(1):385. PubMed ID: 32375688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
    Moore KN; Bookman M; Sehouli J; Miller A; Anderson C; Scambia G; Myers T; Taskiran C; Robison K; Mäenpää J; Willmott L; Colombo N; Thomes-Pepin J; Liontos M; Gold MA; Garcia Y; Sharma SK; Darus CJ; Aghajanian C; Okamoto A; Wu X; Safin R; Wu F; Molinero L; Maiya V; Khor VK; Lin YG; Pignata S
    J Clin Oncol; 2021 Jun; 39(17):1842-1855. PubMed ID: 33891472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secondary cytoreduction surgery for recurrent epithelial ovarian cancer patients after PARPi maintenance: A multicenter, randomized, controlled clinical trial.
    Chen T; Xu J; Xia B; Wang H; Shen Y
    Int J Gynecol Cancer; 2024 Feb; 34(2):328-331. PubMed ID: 38159938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
    Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
    J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
    Morrison J; Haldar K; Kehoe S; Lawrie TA
    Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD005343. PubMed ID: 22895947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.